Chapter 4 · Management
Everyone else
failed at MASH.
They didn't.
Getting the first approval in a graveyard of failed drug programs is the rarest kind of execution.
↓ scroll to read
✦ The bottom line
MASH was infamous for breaking drug programs — many large, well-funded efforts failed in trials. Madrigal designed the trials, generated the data, and won the first approval, then executed a fast commercial launch. That combination — scientific and commercial execution — is what you're betting on.
↓ the brief below
✦ Teach me
Execution where others failed
In biotech the key management question is whether a team can navigate the gauntlet — trial design, regulators, manufacturing, launch — that sinks most companies. Madrigal cleared it in a disease that had specifically defeated rivals for years.
Now the test shifts: from 'can they get a drug approved?' (proven) to 'can they defend and expand a franchise?' as competitors take aim. Different skill, still unproven.
Wall Street calls this
Execution track record
A team that succeeded where many failed has shown rare capability — but the next chapter (defending against bigger rivals) tests skills they haven't had to use yet.